Darbepoetin Alfa MDS Companion Protocol

Status Completed

Clinical Trial Summary

The primary objective of the study was to provide required access of investigational product (darbepoetin alfa) beyond the end of the active treatment period (EOATP) of the darbepoetin alfa MDS 20090160 (NCT01362140) study for patients who had continued demonstration of benefit from darbepoetin alfa treatment and to describe the safety of longer-term use in this patient population.

Clinical Trial Description

This is a phase 3b, multi-centre, open-label, single-arm companion study to the MDS 20090160 study (NCT01362140) for the treatment of anaemic patients with MDS. Participants who completed the active-treatment period of the darbepoetin alfa MDS 20090160 study and met the eligibility criteria could be enrolled into this study to continue treatment of darbepoetin alfa for up to 73 weeks or until progression to acute myelogenous leukemia (AML), whichever occurs first. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02175277
Study type	Interventional
Source	Amgen
Contact
Status	Completed
Phase	Phase 3
Start date	June 12, 2014
Completion date	March 20, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02626715` - Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS	Phase 2
Recruiting	`NCT02905552` - Myelodysplasic Syndromes and Risk Factors for Infection	N/A
Completed	`NCT01772953` - Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT	Phase 2
Suspended	`NCT01211691` - Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)	Phase 1/Phase 2
Active, not recruiting	`NCT06294275` - A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects	Phase 1
Completed	`NCT00533416` - Safety of ON 01910.Na in Patients With Myelodysplasia	Phase 1
Active, not recruiting	`NCT04401748` - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome	Phase 3
Recruiting	`NCT04608110` - A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome	Phase 1
Recruiting	`NCT03613532` - Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN	Phase 1
Withdrawn	`NCT03486353` - A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome	Phase 2
Terminated	`NCT02259348` - Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation	Phase 2
Terminated	`NCT01422486` - Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome	Phase 2
Terminated	`NCT01459159` - Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome	Phase 2
Terminated	`NCT00542828` - Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome	Phase 2
Completed	`NCT01685619` - AML-MDS Novel Prognostic Tests Clinical Study
Recruiting	`NCT01861093` - Safety Study of Cord Blood Units for Stem Cell Transplants	Phase 2
Unknown status	`NCT01983761` - Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation	Phase 1/Phase 2
Recruiting	`NCT01758042` - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders	N/A
Completed	`NCT01338337` - Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia	Phase 2
Completed	`NCT01221857` - Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies	Phase 1/Phase 2